地拉罗司上市没？

Dispersible tablets are also known as Enrig. Deferasirox is a new type of active iron chelator that is highly selective for iron (Fe3+). It is mainly suitable for the treatment of chronic iron overload caused by frequent blood transfusions (monthly dosage of concentrated red blood cells ≥7mL/kg) in patients with β-thalassemia over 6 years old. Today we will take a look at whether deferasirox is on the market?

Maybe many people don’t know much about thalassemia, which is a group of hereditary hemolytic anemia diseases. In recent years, with the increase in incidence, it has gradually entered everyone's field of vision. Currently the best way to treat this disease is through medication. Among them, deferasirox is our most effective drug. Deferasirox is currently the only oral iron chelator developed by Novartis. It was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. In December 2012, Deferasirox was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. On January 23, 2013, the FDA approved a new indication for deferasirox for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT).

Deferasirox is marketed by Novartis and has been approved for marketing in dozens of countries and regions around the world, including China. Deferasirox was previously approved for the treatment of transfusion-induced iron overload in patients 2 years of age and older, and this approval allows deferasirox to be used in patients with NTDT iron overload. Deferasirox should be used in patients with NTDT who have at least 5 mg of iron per 1 g of desiccated liver tissue. The new indication for deferasirox was approved by the FDA through the accelerated approval process, which allows patients to have early access to this promising new drug to treat serious or life-threatening diseases, while the company conducts additional studies to ensure the clinical effectiveness of deferasirox.

The above is the content of the listing, I hope it can help you!